{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:58:50Z","timestamp":1765976330745,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T00:00:00Z","timestamp":1610236800000},"content-version":"am","delay-in-days":344,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jchromb.2020.121968","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T06:14:09Z","timestamp":1578377649000},"page":"121968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["A simple and rapid liquid chromatography-mass spectrometry method to assay cabozantinib in plasma: Application to therapeutic drug monitoring in patients with renal cell carcinoma"],"prefix":"10.1016","volume":"1138","author":[{"given":"Florent","family":"Ferrer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Solas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeline","family":"Giocanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Lacarelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Laurent","family":"Deville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwenaelle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Ciccolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2020.121968_b0005","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jchromb.2020.121968_b0010","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","article-title":"Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update","volume":"94","author":"Choueiri","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jchromb.2020.121968_b0015","first-page":"5053","article-title":"Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma.Onco Targets","volume":"10","author":"Gerendash","year":"2017","journal-title":"Ther"},{"key":"10.1016\/j.jchromb.2020.121968_b0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40262-015-0295-x","article-title":"Population pharmacokinetic model of cabozantinib in patients with medullary thyroid carcinoma and its application to an exposure-response analysis","volume":"55","author":"Miles","year":"2016","journal-title":"ClinPharmacokinet"},{"key":"10.1016\/j.jchromb.2020.121968_b0025","first-page":"1071","article-title":"A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types","volume":"81","author":"Lacy","year":"2018","journal-title":"Cancer ChemotherPharmacol."},{"key":"10.1016\/j.jchromb.2020.121968_b0030","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40262-016-0461-9","article-title":"Clinical pharmacokinetics and pharmacodynamics of cabozantinib","volume":"56","author":"Lacy","year":"2017","journal-title":"ClinPharmacokinet"},{"key":"10.1016\/j.jchromb.2020.121968_b0035","unstructured":"http:\/\/www.ich.org\/products\/guidelines\/multidisciplinary\/multidisciplinary-single\/article\/bioanalytical-method-validation.html."},{"key":"10.1016\/j.jchromb.2020.121968_b0040","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.ejca.2014.04.015","article-title":"Review of therapeutic drug monitoring of anticancer drugs part two\u2013targeted therapies","volume":"50","author":"Widmer","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jchromb.2020.121968_b0045","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3389\/fphar.2017.00523","article-title":"Sunitinib in metastatic renal cell carcinoma: the pharmacological basis of the alternative 2\/1 schedule","volume":"8","author":"Di Paolo","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jchromb.2020.121968_b0050","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1158\/1078-0432.CCR-16-1073","article-title":"Food and drug administration approval: cabozantinib for the treatment of advanced renal cell carcinoma","volume":"23","author":"Singh","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jchromb.2020.121968_b0055","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jchromb.2015.01.024","article-title":"An LC-MS\/MS method for the quantitation of cabozantinib in rat plasma: application to a pharmacokinetic study","volume":"985","author":"Su","year":"2015","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2020.121968_b0060","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4227","article-title":"A sensitive LCMS\/MS method for simultaneous determination of cabozantinib and its metabolite cabozantinib N-oxide in rat plasma and its application in a pharmacokinetic study","volume":"32","author":"Ren","year":"2018","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2020.121968_b0065","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jchromb.2015.01.020","article-title":"Pharmacokinetics and tissue distribution model of cabozantinib in rat determined by UPLC-MS\/MS","volume":"983\u2013984","author":"Wang","year":"2015","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2020.121968_b0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/10408347.2014.980775","article-title":"Biological matrix effects in quantitative Tandem Mass Spectrometry-based analytical methods: advancing biomonitoring","volume":"46","author":"Panuwet","year":"2016","journal-title":"Crit. Rev. Anal. Chem."},{"key":"10.1016\/j.jchromb.2020.121968_b0075","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1124\/dmd.115.063610","article-title":"Metabolism and disposition of cabozantinib in healthy male volunteers and pharmacologic characterization of its major metabolites","volume":"43","author":"Lacy","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jchromb.2020.121968_b0080","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.3793","article-title":"An LC-MS\/MS method for rapid and sensitive high-throughput simultaneous determination of various protein kinase inhibitors in human plasma","volume":"31","author":"Abdelhameed","year":"2017","journal-title":"Biomed. Chromatogr."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023219312632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023219312632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T22:59:20Z","timestamp":1761605960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023219312632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":16,"alternative-id":["S1570023219312632"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2020.121968","relation":{},"ISSN":["1570-0232"],"issn-type":[{"type":"print","value":"1570-0232"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A simple and rapid liquid chromatography-mass spectrometry method to assay cabozantinib in plasma: Application to therapeutic drug monitoring in patients with renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2020.121968","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"121968"}}